Exodus Point Capital Management, LP Liquidia Corp Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$6.63 - $9.9 $311,311 - $464,854	-46,955 Reduced 38.43%	75,216 $590,000
Q1 2023 May 11, 2023	BUY	$5.72 - $7.91 $698,818 - $966,372	122,171 New	122,171 $844,000
Q2 2022 Aug 19, 2022	SELL	$3.37 - $7.55 $482,493 - $1.08 Million	-143,173 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.14 - $7.38 $667,464 - $958,344	129,857 Added 975.2%	143,173 $1.03 Million
Q4 2021 Feb 11, 2022	BUY	$2.71 - $5.17 $36,086 - $68,843	13,316 New	13,316 $65,000
Q3 2021 Nov 15, 2021	SELL	$2.28 - $2.95 $49,569 - $64,135	-21,741 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.51 - $3.11 $54,569 - $67,614	21,741 New	21,741 $62,000
Q1 2021 May 17, 2021	SELL	$2.42 - $3.6 $30,758 - $45,756	-12,710 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.6 - $5.79 $33,046 - $73,590	12,710 New	12,710 $37,000
Q3 2020 Nov 16, 2020	SELL	$4.34 - $8.28 $48,469 - $92,471	-11,168 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$4.86 - $11.44 $80,224 - $188,840	-16,507 Reduced 59.65%	11,168 $94,000
Q1 2020 May 15, 2020	BUY	$3.31 - $7.15 $91,604 - $197,876	27,675 New	27,675 $130,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.